E-Therapeutics Debt 2024

E-Therapeutics Aktienanalyse

What does E-Therapeutics do?

E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It was founded in 2003 by Prof. Malcolm Young and has made significant progress in the field of drug development since then. The company has always aimed for an innovative business model focused on identifying new compounds through computer simulations. E-Therapeutics has developed a unique platform called Network Pharmacology, which simulates complex biological systems and identifies potential drug candidates. The platform uses mathematical models and artificial intelligence to identify molecules that can have a positive effect on specific cells. E-Therapeutics' business model is designed to collaborate with partners in developing new drug candidates. The company offers its platform and expertise to support customers in identifying new chemical compounds. E-Therapeutics works closely with top pharmaceutical companies to advance the development of new drugs. E-Therapeutics is divided into three divisions, each focusing on different areas of medical drug research: 1. Oncology division: This division focuses on developing drugs for the treatment of cancer. E-Therapeutics uses its unique platform to develop targeted therapies tailored to the individual needs of the patient. The platform can also be used to identify new biomarkers and potential therapeutics for a variety of cancer diseases. 2. Neurology division: E-Therapeutics' neurology division focuses on identifying drugs for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and Huntington's. E-Therapeutics' platform has already been used to identify new drug candidates that could have a positive effect on the symptoms of these diseases. 3. Infectious Diseases division: E-Therapeutics' infectious diseases division focuses on the development of drugs for the treatment of infectious diseases such as HIV and influenza. E-Therapeutics uses its platform to identify new compounds that have the potential to fight infections and prevent the spread of diseases. E-Therapeutics has a pipeline of products targeting different medical fields. One promising product is ETS-101, a novel drug candidate for the treatment of pain. ETS-101 has already shown positive results in preclinical studies and is currently in phase 1 studies. Another promising product is ETS-6103, being developed for the treatment of depression. ETS-6103 has been successfully tested in preclinical studies and is currently in phase 2 clinical development. In summary, E-Therapeutics focuses on developing drugs that work at a biological level. The company's innovative business model, unique platform, and collaboration with top pharmaceutical companies make it a key player in medical drug research. With a pipeline of promising products, E-Therapeutics has the potential to change the face of medical drug research and advance the world of medicine. Answer: E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It focuses on identifying new compounds through computer simulations and has developed a unique platform called Network Pharmacology. The company collaborates with partners to develop new drug candidates and is divided into divisions focused on oncology, neurology, and infectious diseases. E-Therapeutics has a pipeline of promising products, including ETS-101 for pain treatment and ETS-6103 for depression treatment. It aims to advance medical drug research and contribute to the field of medicine. E-Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding E-Therapeutics's Debt Structure

E-Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing E-Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to E-Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in E-Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about E-Therapeutics stock

What is the debt of E-Therapeutics this year?

E-Therapeutics has a debt level of -31.39 GBP this year.

What was the debt of E-Therapeutics compared to the previous year?

The debt of E-Therapeutics has increased by 194.5% compared to the previous year increased.

What are the consequences of high debt for investors in E-Therapeutics?

High debt can pose a risk for investors of E-Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of E-Therapeutics?

Low debt means that E-Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from E-Therapeutics affect the company?

An increase in debt of E-Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of E-Therapeutics affect the company?

A reduction in debt of E-Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of E-Therapeutics?

Some factors that can influence the debt of E-Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of E-Therapeutics so important for investors?

The debts of E-Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can E-Therapeutics take to change the debt?

To change the debt, E-Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does E-Therapeutics pay?

Over the past 12 months, E-Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, E-Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of E-Therapeutics?

The current dividend yield of E-Therapeutics is .

When does E-Therapeutics pay dividends?

E-Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of E-Therapeutics?

E-Therapeutics paid dividends every year for the past 0 years.

What is the dividend of E-Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is E-Therapeutics located?

E-Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von E-Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of E-Therapeutics from 11/19/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did E-Therapeutics pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of E-Therapeutics in the year 2023?

In the year 2023, E-Therapeutics distributed 0 GBP as dividends.

In which currency does E-Therapeutics pay out the dividend?

The dividends of E-Therapeutics are distributed in GBP.